Sterigentics International is seeking to turn its Nelson Labs business into a global extractables and leachables lab testing platform through its acquisition of Toxikon’s European division.
The purchase of Toxikon Europe, announced yesterday, represents a capabilities expansion when it comes to serving the pharmaceutical and medical device industries. Sterigenics’s Nelson Labs business will now offer Toxikon Europe’s extractables and leachables testing capabilities to its customers, while Nelson Labs’s microbiological services will be available to Toxikon Europe’s customers.
Financial terms of the deal were not disclosed.
“Toxikon Europe’s geographic foothold and expert analytical testing platform enable our global expansion and ability to provide significantly greater value to customers,” Sterigenics International CEO Michael B. Petras Jr. said in a news release.
The deal includes Nelson Labs and Toxikon USA forming a long-term supply arrangement under which Nelson Labs will outsource in-vivo biocompatibility to Toxikon USA.
“The acquisition of Toxikon Europe and our ongoing partnership with Toxikon USA support our strategy to offer greater breadth of services to meet the demands of our rapidly growing, global customer base,” said Jeff Nelson, President of Nelson Labs.
“We are now able to serve the pharmaceutical and medical device industries continuously from the early stages of product development through manufacturing, sterilization, and testing,” Nelson said.
(Network with Nelson Labs experts at DeviceTalks West, Dec. 11–12 in Orange County, Calif.)
